Los Angeles Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Los Angeles Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-144,269	Closed	-$268K	–	1318
2022 Q2	$268K	Buy	144,269 +1,722	+1%	+$3.29K	﹤0.01%	1182
2022 Q1	$298K	Buy	142,547 +23,680	+20%	+$65.6K	﹤0.01%	1241
2021 Q4	$468K	Sell	118,867 -332	-0.3%	-$1.61K	﹤0.01%	1041
2021 Q3	$573K	Buy	119,199 +60,950	+105%	+$250K	﹤0.01%	991
2021 Q2	$267K	Buy	+58,249	New	+$281K	﹤0.01%	1428
2015 Q2	–	Sell	-2,584	Closed	-$17K	–	1234
2015 Q1	$17K	Hold	2,584	–	–	﹤0.01%	1204
2014 Q4	$16K	Hold	2,584	–	–	﹤0.01%	1105
2014 Q3	$26K	Sell	2,584 -294	-10%	-$3.14K	﹤0.01%	1057
2014 Q2	$32K	Sell	2,878 -36,855	-93%	-$396K	﹤0.01%	1187
2014 Q1	$481K	Buy	+39,733	New	+$508K	0.01%	891

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Los Angeles Capital Management's LXRX Position: Q3 2022 in Review

Los Angeles Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2022, closing a stake of 144,269 shares — an estimated $268K sold.

Los Angeles Capital Management first reported a position in LXRX in Q1 2014 and held it in 10 quarters. The position peaked at $573K in Q3 2021. 98 funds tracked by Wall St. Rank hold LXRX as of Q3 2022.

Los Angeles Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Los Angeles Capital Management sold 144,269 Lexicon Pharmaceuticals shares in Q3 2022, an estimated $268K.
Los Angeles Capital Management first reported a position in Lexicon Pharmaceuticals in Q1 2014 and held it in 10 quarters.
Los Angeles Capital Management's Lexicon Pharmaceuticals position peaked at $573K in Q3 2021.
98 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2022.

Based on Los Angeles Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.